Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
UNION CITY, Calif., July 19, 2011 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the first quarter of fiscal year 2012, ended June 30, 2011. The call will be at 4:15 p.m. ET on Thursday, July 28, 2011. The Company will report financial results for the first quarter of fiscal year 2012 after the market closes on Thursday, July 28, 2011.
Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10002131, through August 3, 2011.
About Abaxis
Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs or rotors, which contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus and Giardia. Abaxis is also in the final stages of building a full-service laboratory testing facility for veterinarians, focusing on specialty and esoteric testing and analysis. This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).
Contact: |
Clint Severson |
Lytham Partners, LLC |
|
Chief Executive Officer |
Joe Dorame, Joe Diaz & Robert Blum |
||
Abaxis, Inc. |
602-889-9700 |
||
510-675-6500 |
|||
SOURCE Abaxis, Inc.
Share this article